Volume 1.12 | Apr 6

Hematopoiesis News 1.12, April 6, 2010.  
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


University of Central Florida Professor Harnesses Plant ‘Power’ to Fight Hemophilia
Treating hemophilia can sometimes be deadly because many patients suffer fatal allergic reactions to the expensive protein that doctors use to make their blood clot. Now researchers have devised a way that could help patients develop a tolerance to the therapeutic protein before they seek treatment to prevent the potentially deadly reactions. [Press release from University of Central Florida discussing online prepublication in Proceedings of the National Academy of Sciences U S A]

Request A Sample  
Column-Free Isolation of
Hematopoietic Stem and Progenitor Cells
with EasySep®


Bone Marrow Cancer Patients May Benefit From Drug Combo
The drugs azacitidine and lenalidomide provide a highly effective combination treatment for bone marrow cancer, according to the results of a new study. [Press release from National Institutes of Health discussing the online prepublication in Journal of Clinical Oncology]

New Use for Once-Cursed Drug Thalidomide?
French doctors, experimenting on mice genetically engineered to have hereditary haemorrhagic telangiectasia, found that Thalidomide reduced the risk of haemorrhage and stabilised blood vessels. [Yahoo! News Press Release]

Watch Procedure Now  
Further Improve Hematopoietic Progenitor Proliferation
with Human LDL
by STEMCELL Technologies



Distinguishing Mast Cell and Granulocyte Differentiation at the Single-Cell Level
The data provide criteria for the prospective isolation of Sca-1(lo)-common myeloid progenitor and Sca-1(lo)-granulocyte/macrophage progenitor and support the conclusion that mast cells are specified during hematopoiesis earlier than and independently from granulocytes. [Cell Stem Cell]

An Evolutionarily Conserved PTEN-C/EBP(Alpha)-CTNNA1 Axis Controls Myeloid Development and Transformation
This study uncovers a novel molecular pathway, PTEN-C/EBP(alpha)-CTNNA1, which might be therapeutically targeted to eradicate leukemia-initiating cells with low CTNNA1 expression. [Blood]

Canonical BMP Signaling is Dispensable for Hematopoietic Stem Cell Function in Both Adult and Fetal Liver Hematopoiesis, But Essential to Preserve Colon Architecture

Here researchers investigate the full role of canonical bone morphogenetic protein (BMP) signaling in both adult and fetal liver hematopoiesis using conditional knockout strategies, since conventional disruption of components of the BMP signaling pathway result in early death of the embryo. [Blood]

Deletion of Proapoptotic Puma Selectively Protects Hematopoietic Stem and Progenitor Cells Against High-Dose Radiation
Here researchers report one pivotal role of the BH3-only protein Puma in the radiosensitivity of hematopoietic stem cells and hematopoietic progenitor cells. [Blood]

Oral Delivery of Bioencapsulated Coagulation Factor IX Prevents Inhibitor Formation and Fatal Anaphylaxis in Hemophilia B Mice
To address complications of pathogenic antibody or life-threatening anaphylactic reactions in protein replacement therapy for patients with hemophilia or other inherited protein deficiencies, researchers have developed a prophylactic protocol using a murine hemophilia B model. [Proc Natl Acad Sci U S A]

Transduction of Human Primitive Repopulating Hematopoietic Cells With Lentiviral Vectors Pseudotyped With Various Envelope Proteins

Researchers examined four envelope proteins for their ability to mediate lentiviral transduction of mobilized human CD34+ peripheral blood cells. [Mol Ther]


Impact of IDH1 R132 Mutations and an IDH1 Single Nucleotide Polymorphism in Cytogenetically Normal Acute Myeloid Leukemia: SNP rs11554137 Is an Adverse Prognostic Factor
Researchers assessed the prognostic impact of IDH1 R132 mutations and a known single nucleotide polymorphism located in the same exon of the IDH1 gene in patients with cytogenetically normal acute myeloid leukemia in the context of other prognostic markers. [J Clin Oncol]

Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial
The purpose of this study was to confirm overall survival and other clinical benefits with bortezomib, melphalan, and prednisone versus melphalan and prednisone in the phase III Velcade as Initial Standard Therapy (VISTA) in Multiple Myeloma trial after prolonged follow-up, and evaluate the impact of subsequent therapies. [J Clin Oncol]

EVI1 Overexpression in Distinct Subtypes of Pediatric Acute Myeloid Leukemia
Researchers studied 228 pediatric acute myeloid leukemia (AML) samples for ecotropic virus integration-1 (EVI1+) using gene expression profiling and RQ-PCR. EVI1+ was found in 20/213 (9%) of children with de novo AML, and in 4/8 with secondary AML. [Leukemia]


Health Reform Will Set Off Biotech Tax Credit Rush
New research credit, capped at $1 billion, should be a bonanza for some small and medium-sized firms and their investors. [Forbes]

Haemonetics Concludes Successful Tender for Global Med Technologies, Inc.
Haemonetics concluded a tender offer to purchase the outstanding shares of Global Med’s common stock at $1.22 per share and preferred stock at approximately $1,694 per share. [Haemonetics Corporation Press Release]

AMAG Pharmaceuticals and Takeda Pharmaceutical Company Announce Strategic Collaboration for Feraheme® in All Therapeutic Indications in Select Ex-US Territories, Including Europe
AMAG Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited jointly announced that the companies have entered into a license, development and commercialization agreement related to Feraheme® (ferumoxytol) Injection for intravenous use in all therapeutic indications. [Takeda Pharmaceutical Company Limited Press Release]

Multiple Myeloma Research Consortium (MMRC) Initiates Phase IB/II Clinical Trial of Treanda® in Combination with Revlimid® and Dexamethasone in Patients with Relapsed Multiple Myeloma
The Multiple Myeloma Research Consortium announced the initiation of a Phase Ib/II study of bendamustine (Treanda®), an anticancer agent currently approved for the treatment of chronic lymphocytic leukemia and B-cell non-Hodgkin’s lymphoma, in combination with lenalidomide (Revlimid®) and dexamethasone in patients with relapsed multiple myeloma. [The Multiple Myeloma Research Consortium Press Release]


Enhancing Peer Review: Updated Processes for the Review of All Ruth L. Kirschstein National Research Service Award Fellowship Applications (NOT-OD-10-071) [National Institutes of Health, United States]

NIH Will Require the Electronic Submission of Appointment Forms and Termination Notices via xTrain for Research Training, Fellowship, Education, and Career Awards Beginning January 2011 (NOT-OD-10-072) [National Institutes of Health, United States]

Small Business Innovation Research Award Levels Adjusted to $150,000 (Phase I) and $1,000,000 (Phase II) (NOT-OD-10-079) [National Institutes of Health, United States]

Notice of Change in Expiration Date for Program Announcement on Bioengineering Research Partnerships (PAR-07-352) (NOT-EB-10-001) [National Institutes of Health, United States]

Revision of the Requirements for Constituent Materials (Docket No. FDA-2010-N-0099) [Food and Drug Administration, United States]

Voting and Nonvoting Consumer Representative Members on Public Advisory Committees and Panels; Notice of Public Meeting (Docket No. FDA-2010-N-0001) [Food and Drug Administration, United States]

Determination of Regulatory Review Period for Purposes of Patent Extension; LUSEDRA (Docket Nos. FDA-2009-E-0202 and FDA-2009-E-0204) [Food and Drug Administration, United States]

Revision of Organization and Conforming Changes to Regulations (Docket No. FDA-2010-N-0148) [Food and Drug Administration, United States]

Administrative Practices and Procedures; Good Guidance Practices; Technical Amendment (Docket No. FDA-1999-N-3539) [Food and Drug Administration, United States]

2010 Biological License Application Supplement Noteworthy Approvals [Food and Drug Administration, United States]


12th Biennial Canadian Blood and Marrow Transplant Group (CBMTG) Conference
April 7-10, 2010
Vancouver, Canada

American Association for Cancer Research (AACR) 101st Annual Meeting 2010
April 17-21, 2010
Washington, DC, United States

International Society for Stem Cell Research (ISSCR) 8th Annual Meeting
June 16-19, 2010
San Francisco, United States

XXXIst International Congress of the International Society of Blood Transfusion (ISBT) in joint cooperation with the 43rd Congress of the German Society for Transfusion Medicine and Immunohematology (DGTI)
June 26-July 1, 2010
Berlin, Germany

Society for Hematology and Stem Cells (ISEH) 2010 Meeting
September 15-18, 2010
Melbourne, Australia

American Association of Blood Banks (AABB) Annual Meeting 2010
October 9-12, 2010
Baltimore, United States

52nd American Society of Hematology (ASH) Annual Meeting and Exposition
December 4-7, 2010
Orlando, United States

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.

Visit here to post your career opportunities.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!


Learn more about Hematopoiesis News: Archives  |  Events  |  Subscribe  |  Contact Us